Helvetica Chimica Acta (2018)
Update date:2022-08-02
Topics:
Herzog, Antoine F.
Schneider, Elia M.
Stark, Wendelin J.
The use of a p-nitrobenzyloxycarbonyl (pNZ) protecting group on the FDA-approved lung cancer drug gemcitabine affords a caged drug with very low in vitro toxicity in a human model cell line (A549). To activate this type of caged potent drug, simultaneous presence of two items is needed: platinum nanoparticles and hydrogen-containing gas mixtures. This combination may later allow a more precise and controlled local delivery of highly potent cytostatic compounds, and may eventually permit reduction of the severe side effects of such chemotherapy treatments. Hydrogen, though an unusual medical agent, is well tolerated, and here used mixtures are derived from diving (deep diving gas). Pt nanoparticles at here used concentrations may eventually be locally deposited into the lungs through minimal invasive inhalation. We demonstrate the use of hydrogen as an on/off uncaging switch and show repeated use of the Pt nanoparticles for a series of uncaging events.
Yingkou Sanzheng Organic Chemical Co. Ltd.
Contact:+86-417-3638818
Address:25 Gengxinli Village, Daqing Road, Yingkou, Liaoning, China
Jiangxi Hito Chemical Co., Ltd.
Contact:+86-792-3170318
Address:No. 6, Tianhong Ave., Xinghuo Industry Park, Yongxiu, Jiujiang, Jiangxi, China
Contact:+86-15995924277
Address:WuZhongOu suzhou new south road 89
Wuhan Better Organic Technology Inc.
Contact:13307163183
Address:Wuhan Economic&Technology Development Zone, Hubei
Shenzhen Sunrising Industry Co., ltd.
Contact:+86 755 86571158 / 86571159 / 86571160
Address:2108 ZHENYE INT. BUSINESS CENTER,NO.3101-90 QIANHAI RD, NANSHAN,SHENZHEN, CHINA
Doi:10.1039/b800815a
(2008)Doi:10.1016/j.bmcl.2007.12.067
(2008)Doi:10.1016/S0040-4039(00)95015-9
(1985)Doi:10.1016/j.carres.2019.107832
(2019)Doi:10.1021/om049443s
(2005)Doi:10.1002/anie.200705822
(2008)
